Compare ResMed Inc. (RMD) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while iShares 10 20 Year Treasury Bond ETF trades at $92.19 (market cap $11.02B). The key difference: ResMed Inc. is far larger — about 2.9× iShares 10 20 Year Treasury Bond ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| RMD | TLH | |
|---|---|---|
Market Cap | $31.89B | $11.02B |
Volume | 618,314 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $275.96 | $105.36 |
52-Week Low | $182.82 | $91.34 |
Typical Hold Time | 51 Days | 60 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
TLH (iShares 10-20 Year Treasury Bond ETF) trades at $92.11, up 0.72% with bearish technical signals from moving averages. The ETF shows unusually high trading volume, up 66% recently, amid a challenging bond market environment where 10-year Treasury yields have reached multi-decade highs. Recent dividend payments of $0.36-$0.38 reflect the fund's income-generating nature.
Outlook remains cautious as rising bond yields pressure long-term Treasury ETFs. Investment opportunity exists for income-focused investors seeking regular dividends, but risks include continued yield increases and Federal Reserve policy uncertainty. The bearish technical picture suggests near-term pressure on bond ETF valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
